Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Taro Iguchi, MD, PHD
With
Astellas Pharma Inc
Age
20–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Testosterone of less than 50 ng/dL
Participants who was detected of disease progression on image or relapse of PSA (All PSA values measured 3 time at least one week interval are consecutively increased and final value is 2 ng/mL or more. If third value is not higher than second one, fourth measurement will be undertaken and its value must be higher than second one.)
Participants who relapsed after CAB with bicalutamide
Eastern Cooperative Oncology Group (ECOG) performance status is 0 or 1
Aged 20 years or older
Participants who provided written informed consent
You may not be if
Any prior treatment with enzalutamide, flutamide, abiraterone or chemotherapy, except for neoadjuvant therapy
With active double cancer
Any prior treatment with bicalutamide within 6 weeks
Participants who received systemic biological therapy (except for existing approved drug for bone or treatment with luteinizing hormone-releasing hormone (LHRH) analogue) or received treatment with other antitumor agent for prostate cancer
With serious complication
History of hypersensitivity to enzalutamide or any other excipient of enzalutamide
History of hypersensitivity to flutamide-containing agent
With liver dysfunction
Participants who are considered as inadequate by the investigator
Clareo Health | Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.
